Cytonix Receives Exclusive License from the National Institutes of Health for Single Molecule DNA Detection
News Mar 21, 2007
Cytonix Corporation announced that it has signed an exclusive license with the National Institutes of Health (NIH) for a method of sampling, amplifying and quantifying nucleic acids and for the production of nanoliter devices needed for the application of this technology.
The technology allows Cytonix to capture a single nucleic acid molecule in a nanoarray vastly facilitating the detection and identification of signature DNA or RNA molecules. The nanoarrays from Cytonix will make it possible to count the number of DNA or RNA molecules captured as the unit of absolute quantity.
James F. Brown, VP of Cytonix is a co-inventor of this patented technology: U.S. patent No. 6,143,496 (issued November 7, 2000 entitled “Methods of Sampling, Amplifying and Quantifying Segment of Nucleic Acid” and for U.S. Patent Application Serial No. 10/131,854 (‘854, filed April 25, 2002, publication No. 20020164820), entitled “Method of sampling, amplifying and quantifying segment of nucleic acid, polymerase chain reaction assembly having nanoliter-sized sample chambers, and method of filling assembly.”
According to Mr. Brown, “this technology provides Cytonix Corporation the unique ability to identify a single molecule of contaminating DNA in food, water or blood by simply counting the number of fluorescent wells in a nanoarray chamber and provides for the first time a true quantitative procedure for measuring nucleic acids.”
According to Cytonix, the technology offers an alternative to traditional real time quantitative-PCR (qPCR) as a means of quantifying nucleic acids and treats every nucleic acid molecule as an individual, overcoming a major limitation of current PCR procedures in detecting rare sequence differences.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.